By: IPP Bureau
Last updated : August 14, 2026 6:39 pm
Diagnostics chain's board sets AGM for September 28, and approves issuance of warrants to Chairman Rajendra Mutha and promoter entity at price of Rs. 565 per warrant
Krsnaa Diagnostics Limited's Board of Directors, at a meeting held on August 13, 2026, approved the company's unaudited financial results for the quarter ended June 30, 2026, along with several other key items including a preferential issue of share warrants to promoters.
On a consolidated basis, revenue from operations for the quarter stood at Rs. 2,355.32 million, up from Rs. 1,929.78 million in the same quarter last year and Rs. 1,926.04 million in the preceding quarter.
Total income came in at Rs. 2,427.72 million. Profit before tax stood at Rs. 224.36 million, compared to Rs. 274.22 million in Q1 FY26, while profit for the period was Rs. 165.51 million, down from Rs. 205.20 million a year earlier. Basic earnings per share stood at Rs. 5.10, compared to Rs. 6.35 in Q1 FY26.
On a standalone basis, revenue from operations was Rs. 2,106.61 million, up from Rs. 1,756.15 million in Q1 FY26. Profit before tax stood at Rs. 215.16 million, against Rs. 263.37 million a year earlier, with profit for the period at Rs. 158.20 million, down from Rs. 195.62 million.
Standalone basic EPS came in at Rs. 4.88, compared to Rs. 6.10 in the year-ago quarter.
Among the items approved at the meeting, the Board cleared the issuance of up to 16,21,000 share warrants to Chairman & Whole-time Director Rajendra Mutha and Krsna Diagnostics (Mumbai) Private Limited, both classified as Promoter and Promoter Group.
The warrants will be issued on a preferential, private-placement basis under the Companies Act, 2013, and SEBI's ICDR Regulations, 2018, at a price that will be the higher of the future floor price as determined under SEBI regulations or Rs. 565 per warrant.